Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review
Authors
Keywords
-
Journal
PHARMACOECONOMICS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-02-03
DOI
10.1007/s40273-021-01121-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Systemic therapy, survival and end-of-life costs for metastatic triple-negative breast cancer: retrospective SEER-Medicare study of women age ≥65 years
- (2021) Jan Sieluk et al. Future Oncology
- PCN248 Productivity Costs Associated with Disease Recurrence Among Surgically-Treated Patients with Triple-Negative Breast Cancer
- (2021) J. Sieluk et al. VALUE IN HEALTH
- PCN240 Healthcare Resource Utilization Associated with Disease Recurrence Among Surgically-Treated Patients with Triple-Negative Breast Cancer
- (2021) J. Sieluk et al. VALUE IN HEALTH
- Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer
- (2020) S. Adams et al. ANNALS OF ONCOLOGY
- 141P Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple negative breast cancer
- (2020) P. Schmid et al. ANNALS OF ONCOLOGY
- 104P Cost and healthcare resource utilization (HCRU) for patients receiving neoadjuvant therapy for early-stage triple-negative breast cancer (ESTNBC)
- (2020) W.C. Rhodes et al. ANNALS OF ONCOLOGY
- Quality of life among breast cancer survivors with triple negative breast cancer—role of hope, self-efficacy and social support
- (2020) Aomei Shen et al. European Journal of Oncology Nursing
- PCN314 REAL-WORLD PATIENT DEMOGRAPHICS, TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION (HRU) AMONG HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC) PATIENTS WITH BRCA1/2 MUTATIONS (BRCA1/2MUT)
- (2020) R.C. Parikh et al. VALUE IN HEALTH
- PCN308 HEALTH UTILITY IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC TNBC
- (2020) M. Huang et al. VALUE IN HEALTH
- Variability in hospital treatment costs: a time-driven activity-based costing approach for early-stage invasive breast cancer patients
- (2020) Erin Roman et al. BMJ Open
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)†
- (2020) F. Cardoso et al. ANNALS OF ONCOLOGY
- Health-related quality of life in breast cancer patients: review of reviews from 2008 to 2018
- (2020) Parisa Mokhatri-Hesari et al. Health and Quality of Life Outcomes
- Treatment patterns, risk for hospitalization and mortality in older patients with triple negative breast cancer
- (2020) Antonis Valachis et al. Journal of Geriatric Oncology
- A population‐based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple‐negative breast cancer
- (2020) Christine Brezden‐Masley et al. Cancer Medicine
- Early triple-negative breast cancer in women aged ≥65: retrospective study of outcomes, resource use and costs, 2010–2016
- (2020) Jan Sieluk et al. Future Oncology
- Assessing direct costs of treating metastatic triple-negative breast cancer in the USA
- (2020) Karen E Skinner et al. Journal of Comparative Effectiveness Research
- Breast Cancer Treatment
- (2019) Adrienne G. Waks et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Overall survival, costs and healthcare resource use by number of regimens received in elderly patients with newly diagnosed metastatic triple-negative breast cancer
- (2019) Abdalla Aly et al. Future Oncology
- Advocacy for a New Oncology Research Paradigm: The Model of Bevacizumab in Triple-Negative Breast Cancer in a French Cohort Study
- (2019) Benoîte Mery et al. ONCOLOGY
- Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2019) F Cardoso et al. ANNALS OF ONCOLOGY
- PCN58 HUMANISTIC AND ECONOMIC BURDENS OF TRIPLE-NEGATIVE BREAST CANCER: A LITERATURE REVIEW
- (2019) A. Fu et al. VALUE IN HEALTH
- Adjusting for Inflation and Currency Changes Within Health Economic Studies
- (2019) Hugo C. Turner et al. VALUE IN HEALTH
- PCN132 SYSTEMATIC REVIEW OF ECONOMIC BURDEN IN TRIPLE-NEGATIVE BREAST CANCER PATIENTS
- (2019) A. Frederickson et al. VALUE IN HEALTH
- PCN468 SYSTEMATIC REVIEW OF UTILITY ESTIMATES IN TRIPLE-NEGATIVE BREAST CANCER PATIENTS
- (2019) A. Frederickson et al. VALUE IN HEALTH
- Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States
- (2018) Kendra L. Schwartz et al. CANCER
- Outcomes research examining treatments, quality of life and costs in HER2-negative and triple-negative metastatic breast cancer: a systematic literature review
- (2018) Monika Parisi et al. Journal of Comparative Effectiveness Research
- The economic burden of metastatic breast cancer in Spain
- (2018) Begoña Bermejo de las Heras et al. European Journal of Hospital Pharmacy-Science and Practice
- 292OPatient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): A focus on the EMBRACA triple negative (TNBC) subpopulation
- (2018) H S Rugo et al. ANNALS OF ONCOLOGY
- Productivity Costs Associated With Breast Cancer Among Survivors Aged 18–44 Years
- (2016) Donatus U. Ekwueme et al. AMERICAN JOURNAL OF PREVENTIVE MEDICINE
- Cancer Associated Medical Spending: US National Data Between 2000 and 2013
- (2016) J Zhuo et al. VALUE IN HEALTH
- Exercise and dietary advice intervention for survivors of triple-negative breast cancer: effects on body fat, physical function, quality of life, and adipokine profile
- (2015) Anne K. Swisher et al. SUPPORTIVE CARE IN CANCER
- Elicitation of Health-Related Quality-of-Life Concepts Associated With Triple-Negative Breast Cancer
- (2015) S Holmstrom et al. VALUE IN HEALTH
- TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases
- (2014) Carey Anders et al. BREAST CANCER RESEARCH AND TREATMENT
- The economic burden of metastatic breast cancer: a U.S. managed care perspective
- (2012) Alberto J. Montero et al. BREAST CANCER RESEARCH AND TREATMENT
- Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry
- (2012) Onur Baser et al. CURRENT MEDICAL RESEARCH AND OPINION
- Economic Burden of Cancer in the United States: Estimates, Projections, and Future Research
- (2011) K. R. Yabroff et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials
- (2008) Kim Cocks et al. EUROPEAN JOURNAL OF CANCER
- Evaluation of Trends in the Cost of Initial Cancer Treatment
- (2008) J. L. Warren et al. JNCI-Journal of the National Cancer Institute
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now